Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.8452W HIGH $16.55
Volume
34.36 K
Value Traded
178.69 K
Short % Float
0.94%
-3.73%Week
-8.11%1 Month
-9.9%3 Month
-15.33%6 Month
-97.82%5 Year
-99.46%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
63.30 M
EPS (TTM)
-3.64
P/E Ratio
-
Ent. Value
80.41 M
Total Shares
9.80 M
Float Shares
8.29 M
Insiders
15.36%
Institutions
8.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DRIO Catalyst Timeline
Dated clinical, regulatory and corporate events for DarioHealth Corp.
Past FDA Catalysts and PDUFA Decisions
How DRIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
DarioHealth Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DRIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Dario | Type 2 Diabetes | 2023-10-17 | hospital readmission reduction: 36%; hospital days reduction: 1.6; Hb A1c control improvement: 9%; poor control reduction: 13%Read More | New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 DiabetesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Matheis DennisDirector | Buy | 14,430 43,026 held | $6.93 | 07/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DRIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 1.29 M | 313.87 K | -4.27% ( -14.00 K) |
DRIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DRIO ranks across every disease it competes in
Competitive Position is a premium feature
See how DRIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDRIO News
DRIODarioHealth Reports Second Quarter 2026 Financial Results
DarioHealth Corp. reported its second quarter 2026 financial results, showing a revenue of $5.2 million, a decrease from the previous quarter. The company achieved a gross margin of 62%, up from 57% in Q1 2026, and reduced its operating loss by 30% year-over-year. DarioHealth is expanding its multi-condition platform and has secured significant new clients, enhancing its revenue potential.
Read more →DRIODarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026
DarioHealth Corp. will announce its financial results for Q2 2026 on August 11, 2026. The company, known for its AI-driven healthcare solutions, will host a conference call at 8:30 a.m. ET, featuring key executives. This event aims to provide insights into the company's performance and future strategies.
Read more →DRIO▲ +12.9%on this news
Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
DarioHealth Corp. has announced a registered direct offering of common stock, raising approximately $23.5 million. The offering, priced at $6.80 per share, involves participation from existing long-term investors and new institutional investors. The funds will be utilized for working capital, investments, and general corporate purposes, with the closing expected on July 23, 2026.
Read more →DRIODario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership
DarioHealth Corp. has signed a new agreement with a major health insurer in Arizona through its partnership with Amwell. This agreement allows Dario's cardiometabolic digital health solutions to be offered to a large population of self-insured employers. The initiative aims to reduce cardiometabolic risks and costs while providing tailored health solutions to meet specific employer needs.
Read more →DRIO▲ +7.9%on this newsshared move
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
DarioHealth Corp. has expanded its partnership with a major U.S. health insurer, adding hypertension solutions to its existing behavioral health offerings. This extension is expected to triple revenue opportunities under this customer relationship, reinforcing Dario's multi-condition care strategy. The company aims to improve health outcomes while reducing costs through integrated care solutions.
Read more →DRIODario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships
DarioHealth Corp. has appointed Sean O'Reilly, former Chief Compliance Officer at Humana, to its Advisory Board. His extensive experience in healthcare compliance and risk management is expected to support Dario's growth strategy and enhance its relationships with health plans, employers, and providers. O'Reilly's background in leveraging AI for value-based care aligns with Dario's mission to improve healthcare outcomes.
Read more →DRIODario Announces Strategic Collaboration with Beluga Health to Deliver Provider-Backed, Integrated Care at Scale
DarioHealth Corp. has announced a strategic collaboration with Beluga Health to enhance its digital health solutions. This partnership aims to provide a provider-backed, integrated care model that combines Dario's chronic care platform with Beluga's clinical network. The collaboration is expected to improve member engagement, lower healthcare costs, and expand into new markets, positioning Dario as a key player in value-based care.
Read more →DRIODario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
DarioHealth Corp. presented notable findings at the American Diabetes Association Scientific Sessions, showcasing the effectiveness of its digital health platform in managing chronic conditions like diabetes and obesity. The studies highlighted that sustained engagement with the platform leads to improved clinical outcomes, as evidenced by significant weight loss and reductions in hospitalizations among high-risk patients. Findings indicate potential cost savings for payers and a compelling case for enterprise buyers to adopt integrated solutions for better patient management across multiple chronic conditions. With a total of 27 studies presented over eight years, Dario reinforces its strategic move towards value-based healthcare.
Read more →DRIODario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives
DarioHealth Corp. has expanded its hypertension program through a partnership with Solera Health, significantly increasing its addressable market to over 500,000 eligible lives. This initiative targets a broader population, including pre-hypertensive individuals, and aligns revenue with clinical outcomes. DarioHealth's capabilities in engaging members and delivering value across cardiometabolic conditions are emphasized as key strengths.
Read more →DRIO▼ -6.7%on this news
DarioHealth Reports First Quarter 2026 Financial and Operating Results
DarioHealth Corp. reported its first quarter 2026 financial results, highlighting a second consecutive quarter of sequential revenue growth and reduced operating expenses. The company is expanding its channel partner ecosystem, now reaching over 116 million covered lives. However, it faced a year-over-year revenue decline due to the non-recurrence of previous revenues. Despite operational improvements, the net loss increased compared to the prior year.
Read more →DRIODarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
DarioHealth Corp. will announce its financial results for Q1 2026 on May 13, 2026. The company will host a conference call at 8:30 a.m. ET, featuring key executives. The call will be accessible via dial-in and webcast, with a replay available post-event. DarioHealth focuses on digital therapeutics for chronic conditions.
Read more →DRIODario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research
DarioHealth Corp. announced a study published in JMIR Formative Research, showing significant improvements in workplace functioning through its digital behavioral health program. The study involved 1,254 users and demonstrated enhanced focus, productivity, and task completion. These findings underscore the economic benefits of Dario's solutions for employers and health plans, addressing the link between behavioral health and workforce productivity.
Read more →DRIODario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling
DarioHealth Corp. has appointed John R. Palumbo to its Board of Directors to aid in commercial scaling. With over 40 years of healthcare experience, Palumbo's strategic insights and industry relationships are anticipated to enhance Dario's growth trajectory. His background includes leadership roles in major healthcare organizations, making him a valuable asset as Dario aims to expand its market presence.
Read more →DRIO▼ -7.7%on this news
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
DarioHealth Corp. reported its financial results for the fourth quarter and full year of 2025, highlighting a sequential revenue increase to $5.2 million and a full-year revenue of $22.4 million. The decline in annual revenue was attributed to the non-renewal of a large client post-Twill acquisition, but the company noted substantial growth in contracted annual recurring revenue, projecting strong growth into 2026 and 2027. The financial results also revealed improved gross margins and a substantial reduction in operating expenses, with a focus on expanding commercial opportunities and new agreements signed. Overall, DarioHealth's pipeline and operating trends suggest a positive outlook despite challenges in annual revenue figures.
Read more →DRIODarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
DarioHealth Corp. will release its financial results for the fourth quarter of 2025 on March 19, 2026, ahead of the market opening. The announcement includes details for a conference call and webcast scheduled for 8:30 a.m. Eastern Time, featuring executive leadership. The call will discuss DarioHealth's performance and business outlook, marking an important event for stakeholders. A replay option will be available for those unable to attend the live event.
Read more →DRIODario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health
DarioHealth Corp. announced the publication of a peer-reviewed study in Frontiers in Digital Health, revealing significant blood glucose improvements among over 22,000 users of its platform. The research utilized machine learning to analyze real-world data and found a strong correlation between digital engagement and health outcomes. Key insights suggest that users monitoring their glucose regularly experienced better results, allowing for personalized diabetes management strategies. The findings confirm Dario's ability to drive measurable clinical impact through tailored health solutions.
Read more →DRIODario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
DarioHealth Corp. has reported a growing demand for its digital health solutions tailored for oral GLP-1 therapies. With 79% of its members utilizing weight management support, Dario aims to optimize medication outcomes through structured behavioral reinforcement. As oral GLP-1s are expected to capture a significant market share, Dario's approach focuses on enhancing adherence and long-term health outcomes for users.
Read more →DRIODario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms
DarioHealth Corp. has announced a significant milestone by surpassing 100 scientific studies, including peer-reviewed publications. This achievement positions Dario among the leading digital health vendors, emphasizing its commitment to delivering validated outcomes. The company’s research is distinguished by its scientific rigor, appealing to organizations seeking measurable impacts in health delivery.
Read more →DRIODario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members
DarioHealth Corp. has launched the Dario Health app with DarioIQ™, an AI integration aimed at enhancing user experience for hypertension management. This marks a significant milestone in Dario's GenAI roadmap, focusing on patient safety and personalized guidance. The initial rollout will help refine the AI experience before expanding to other chronic conditions.
Read more →DRIODario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio
DarioHealth Corp. announced a peer-reviewed study published in JMIR Cardio, demonstrating that their data-driven digital health platform significantly improves blood pressure outcomes. The study found that users receiving digital nudges experienced a greater reduction in systolic blood pressure compared to a control group. This evidence suggests that personalized digital interventions can effectively manage hypertension over the long term.
Read more →About DarioHealth Corp.
Headquarters322 W 57TH ST. #33B, NEW YORK, NY, 10019
BIOPHARMAWATCH ELITE PLUS
Trade the next DRIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime